vs
Arcosa, Inc.（ACA）与博士伦（BLCO）财务数据对比。点击上方公司名可切换其他公司
博士伦的季度营收约是Arcosa, Inc.的2.0倍（$1.4B vs $716.7M），Arcosa, Inc.净利率更高（7.3% vs -4.1%，领先11.4%），博士伦同比增速更快（9.8% vs 7.6%），博士伦自由现金流更多（$60.0M vs $55.8M），过去两年博士伦的营收复合增速更高（13.1% vs 9.4%）
Arcosa, Inc.是一家基础设施相关产品及解决方案提供商，业务覆盖建筑、能源、交通三大核心板块，主营公用设施结构件、建筑集料、交通零部件等产品，主要面向北美市场客户，为各类关键基础设施建设项目提供支持。
博士伦是知名眼健康产品企业，总部位于加拿大安大略省沃恩市，是全球规模最大的隐形眼镜、镜片护理产品、眼科药品、人工晶体及其他眼科手术产品供应商之一。品牌1853年由验光师约翰·鲍什与合伙人亨利·朗姆在美国纽约罗切斯特创立，曾是美国历史最悠久的持续运营企业之一，2013年被整体收购。
ACA vs BLCO — 直观对比
营收规模更大
BLCO
是对方的2.0倍
$716.7M
营收增速更快
BLCO
高出2.2%
7.6%
净利率更高
ACA
高出11.4%
-4.1%
自由现金流更多
BLCO
多$4.2M
$55.8M
两年增速更快
BLCO
近两年复合增速
9.4%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $716.7M | $1.4B |
| 净利润 | $52.1M | $-58.0M |
| 毛利率 | 22.9% | — |
| 营业利润率 | 11.0% | 8.0% |
| 净利率 | 7.3% | -4.1% |
| 营收同比 | 7.6% | 9.8% |
| 净利润同比 | 776.6% | -1833.3% |
| 每股收益（稀释后） | $1.06 | $-0.16 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ACABLCO
| Q4 25 | $716.7M | $1.4B | ||
| Q3 25 | $797.8M | $1.3B | ||
| Q2 25 | $736.9M | $1.3B | ||
| Q1 25 | $632.0M | $1.1B | ||
| Q4 24 | $666.2M | $1.3B | ||
| Q3 24 | $640.4M | $1.2B | ||
| Q2 24 | $664.7M | $1.2B | ||
| Q1 24 | $598.6M | $1.1B |
净利润ACABLCO
| Q4 25 | $52.1M | $-58.0M | ||
| Q3 25 | $73.0M | $-28.0M | ||
| Q2 25 | $59.7M | $-62.0M | ||
| Q1 25 | $23.6M | $-212.0M | ||
| Q4 24 | $-7.7M | $-3.0M | ||
| Q3 24 | $16.6M | $4.0M | ||
| Q2 24 | $45.6M | $-151.0M | ||
| Q1 24 | $39.2M | $-167.0M |
毛利率ACABLCO
| Q4 25 | 22.9% | — | ||
| Q3 25 | 24.1% | — | ||
| Q2 25 | 22.5% | — | ||
| Q1 25 | 19.8% | — | ||
| Q4 24 | 19.3% | — | ||
| Q3 24 | 21.3% | — | ||
| Q2 24 | 20.8% | — | ||
| Q1 24 | 18.6% | — |
营业利润率ACABLCO
| Q4 25 | 11.0% | 8.0% | ||
| Q3 25 | 14.1% | 7.4% | ||
| Q2 25 | 12.9% | -0.9% | ||
| Q1 25 | 8.8% | -7.3% | ||
| Q4 24 | 6.5% | 6.8% | ||
| Q3 24 | 5.3% | 3.6% | ||
| Q2 24 | 10.1% | 2.1% | ||
| Q1 24 | 8.9% | 0.5% |
净利率ACABLCO
| Q4 25 | 7.3% | -4.1% | ||
| Q3 25 | 9.2% | -2.2% | ||
| Q2 25 | 8.1% | -4.9% | ||
| Q1 25 | 3.7% | -18.6% | ||
| Q4 24 | -1.2% | -0.2% | ||
| Q3 24 | 2.6% | 0.3% | ||
| Q2 24 | 6.9% | -12.4% | ||
| Q1 24 | 6.5% | -15.2% |
每股收益（稀释后）ACABLCO
| Q4 25 | $1.06 | $-0.16 | ||
| Q3 25 | $1.48 | $-0.08 | ||
| Q2 25 | $1.22 | $-0.18 | ||
| Q1 25 | $0.48 | $-0.60 | ||
| Q4 24 | $-0.16 | $-0.00 | ||
| Q3 24 | $0.34 | $0.01 | ||
| Q2 24 | $0.93 | $-0.43 | ||
| Q1 24 | $0.80 | $-0.48 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $214.6M | $383.0M |
| 总债务越低越好 | $1.5B | $5.0B |
| 股东权益账面价值 | $2.6B | $6.4B |
| 总资产 | $5.0B | $14.0B |
| 负债/权益比越低杠杆越低 | 0.57× | 0.78× |
8季度趋势，按日历期对齐
现金及短期投资ACABLCO
| Q4 25 | $214.6M | $383.0M | ||
| Q3 25 | $220.0M | $310.0M | ||
| Q2 25 | $189.7M | $266.0M | ||
| Q1 25 | $167.9M | $202.0M | ||
| Q4 24 | $187.3M | $305.0M | ||
| Q3 24 | $756.8M | $329.0M | ||
| Q2 24 | $103.7M | $285.0M | ||
| Q1 24 | $176.5M | $315.0M |
总债务ACABLCO
| Q4 25 | $1.5B | $5.0B | ||
| Q3 25 | $1.6B | $5.0B | ||
| Q2 25 | $1.7B | $5.0B | ||
| Q1 25 | $1.7B | $4.8B | ||
| Q4 24 | $1.7B | $4.8B | ||
| Q3 24 | $1.2B | $4.6B | ||
| Q2 24 | $699.9M | $4.6B | ||
| Q1 24 | $600.6M | $4.6B |
股东权益ACABLCO
| Q4 25 | $2.6B | $6.4B | ||
| Q3 25 | $2.6B | $6.4B | ||
| Q2 25 | $2.5B | $6.4B | ||
| Q1 25 | $2.5B | $6.4B | ||
| Q4 24 | $2.4B | $6.5B | ||
| Q3 24 | $2.4B | $6.6B | ||
| Q2 24 | $2.4B | $6.5B | ||
| Q1 24 | $2.4B | $6.7B |
总资产ACABLCO
| Q4 25 | $5.0B | $14.0B | ||
| Q3 25 | $5.1B | $13.8B | ||
| Q2 25 | $5.0B | $13.8B | ||
| Q1 25 | $4.9B | $13.4B | ||
| Q4 24 | $4.9B | $13.5B | ||
| Q3 24 | $4.4B | $13.5B | ||
| Q2 24 | $3.8B | $13.3B | ||
| Q1 24 | $3.7B | $13.3B |
负债/权益比ACABLCO
| Q4 25 | 0.57× | 0.78× | ||
| Q3 25 | 0.61× | 0.77× | ||
| Q2 25 | 0.67× | 0.77× | ||
| Q1 25 | 0.68× | 0.76× | ||
| Q4 24 | 0.69× | 0.74× | ||
| Q3 24 | 0.51× | 0.70× | ||
| Q2 24 | 0.29× | 0.71× | ||
| Q1 24 | 0.25× | 0.69× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $120.0M | $136.0M |
| 自由现金流经营现金流 - 资本支出 | $55.8M | $60.0M |
| 自由现金流率自由现金流/营收 | 7.8% | 4.3% |
| 资本支出强度资本支出/营收 | 9.0% | 5.4% |
| 现金转化率经营现金流/净利润 | 2.30× | — |
| 过去12个月自由现金流最近4个季度 | $175.5M | $-66.0M |
8季度趋势，按日历期对齐
经营现金流ACABLCO
| Q4 25 | $120.0M | $136.0M | ||
| Q3 25 | $160.6M | $137.0M | ||
| Q2 25 | $61.2M | $35.0M | ||
| Q1 25 | $-700.0K | $-25.0M | ||
| Q4 24 | $248.2M | $22.0M | ||
| Q3 24 | $135.0M | $154.0M | ||
| Q2 24 | $38.3M | $15.0M | ||
| Q1 24 | $80.5M | $41.0M |
自由现金流ACABLCO
| Q4 25 | $55.8M | $60.0M | ||
| Q3 25 | $121.0M | $63.0M | ||
| Q2 25 | $33.4M | $-54.0M | ||
| Q1 25 | $-34.7M | $-135.0M | ||
| Q4 24 | $194.9M | $-70.0M | ||
| Q3 24 | $100.6M | $94.0M | ||
| Q2 24 | $-9.3M | $-57.0M | ||
| Q1 24 | $26.1M | $-26.0M |
自由现金流率ACABLCO
| Q4 25 | 7.8% | 4.3% | ||
| Q3 25 | 15.2% | 4.9% | ||
| Q2 25 | 4.5% | -4.2% | ||
| Q1 25 | -5.5% | -11.9% | ||
| Q4 24 | 29.3% | -5.5% | ||
| Q3 24 | 15.7% | 7.9% | ||
| Q2 24 | -1.4% | -4.7% | ||
| Q1 24 | 4.4% | -2.4% |
资本支出强度ACABLCO
| Q4 25 | 9.0% | 5.4% | ||
| Q3 25 | 5.0% | 5.8% | ||
| Q2 25 | 3.8% | 7.0% | ||
| Q1 25 | 5.4% | 9.7% | ||
| Q4 24 | 8.0% | 7.2% | ||
| Q3 24 | 5.4% | 5.0% | ||
| Q2 24 | 7.2% | 5.9% | ||
| Q1 24 | 9.1% | 6.1% |
现金转化率ACABLCO
| Q4 25 | 2.30× | — | ||
| Q3 25 | 2.20× | — | ||
| Q2 25 | 1.03× | — | ||
| Q1 25 | -0.03× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 8.13× | 38.50× | ||
| Q2 24 | 0.84× | — | ||
| Q1 24 | 2.05× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ACA
| Engineered Structures | $301.1M | 42% |
| Total Construction Materials | $276.8M | 39% |
| Specialty Materials And Asphalt | $110.2M | 15% |
| Construction Site Support | $28.6M | 4% |
BLCO
| Overthe Counter Products | $489.0M | 35% |
| Pharmaceuticals | $378.0M | 27% |
| Other | $263.0M | 19% |
| Surgical | $249.0M | 18% |
| Brandedand Other Generic Products | $14.0M | 1% |
| Other Revenues | $3.0M | 0% |
| Pharmaceutical Products | $2.0M | 0% |
